<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02806570</url>
  </required_header>
  <id_info>
    <org_study_id>4433</org_study_id>
    <nct_id>NCT02806570</nct_id>
  </id_info>
  <brief_title>Early Feasibility Study of the AccuCinch® Ventricular Repair System - The CorCinch-FMR Study</brief_title>
  <official_title>Early Feasibility Study of the AccuCinch® Ventricular Repair System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ancora Heart, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ancora Heart, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, non-randomized, prospective Early Feasibility Study to evaluate the
      AccuCinch® Ventricular Repair System in patients with symptomatic heart failure and
      concomitant functional mitral regurgitation that have stable symptoms on guideline-directed
      medical therapy
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30-Day Safety</measure>
    <time_frame>30-day</time_frame>
    <description>Assess 30-day safety defined as device-related or procedure-related major adverse events (MAEs).
MAE is a composite of death; myocardial infarction; emergent conversion to surgery; stroke; major cardiac structure complication; major vascular complication; and heart failure-related hospitalization.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Heart Failure</condition>
  <condition>Mitral Valve Insufficiency</condition>
  <condition>Cardiomyopathies</condition>
  <arm_group>
    <arm_group_label>AccuCinch® Ventricular Repair System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mitral valve repair</intervention_name>
    <arm_group_label>AccuCinch® Ventricular Repair System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Study patient is at least 18-years old

          -  Severity of FMR: ≥ Moderate (i.e., 2+, according to Stone et al Clinical Trial Design
             Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and
             Replacement: Part 1: Clinical Trial Design Principles. A Consensus Document from the
             Mitral Valve Academic Research Consortium11; and 2003 ASE Guidelines for grading
             mitral regurgitation10)

          -  Ejection Fraction: ≥20 to ≤60%

          -  Symptom Status: NYHA II-IV (i.e., ambulatory)

          -  Treatment and compliance with optimal guideline directed medical therapy for heart
             failure for at least 1 month

          -  Surgical risk: Subject is eligible for cardiac surgery (specific risk score or
             comorbidities should demonstrate high risk features, as determined by the Heart Team)

          -  Completion of all qualifying diagnostic and functional tests and agrees to comply with
             study follow-up schedule

        Exclusion Criteria:

          -  Patients with significant organic mitral valve pathology (e.g. myxomatous
             degeneration, mitral valve prolapse or flail leaflets)

          -  Myocardial infarction or any percutaneous cardiovascular intervention, cardiovascular
             surgery, or carotid surgery within 30 days

          -  Prior surgical, transcatheter, or percutaneous mitral valve intervention

          -  Untreated clinically significant coronary artery disease (CAD) requiring
             revascularization

          -  Hemodynamic instability: Hypotension (systolic pressure &lt;90 mmHg) or requirement for
             inotropic support or mechanical hemodynamic support

          -  Any planned cardiac surgery or interventions within the next 6 months (including right
             heart procedures)

          -  NYHA class IV (i.e., non-ambulatory) or ACC/AHA Stage D heart failure

          -  Fixed pulmonary artery systolic pressure &gt;70 mmHg

          -  Severe tricuspid regurgitation (per ASE guidelines and graded by the Echo Core Lab)

          -  Modified Rankin Scale ≥ 4 disability

          -  Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or
             any other structural heart disease causing heart failure other than dilated
             cardiomyopathy of either ischemic or non-ischemic etiology.

          -  Anatomical pathology/constraints preventing appropriate access/implant of the
             AccuCinch® Ventricular Repair System (e.g., femoral arteries will not support a 20F
             system)

          -  Renal insufficiency (i.e., eGFR of &lt;30ml/min/1.73m2; Stage 4 or 5 CKD)

          -  Moderate or severe aortic valve stenosis or regurgitation or aortic valve prosthesis

          -  Fluoroscopic or echocardiographic evidence of severe aortic arch calcification, mobile
             aortic atheroma, intracardiac mass, thrombus or vegetation

          -  Active bacterial endocarditis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Zapien, MS, CCRA</last_name>
    <role>Study Director</role>
    <affiliation>Ancora Heart, Inc. (formerly Guided Delivery Systems Inc.)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dean Kereiakes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christ Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Satya Shreenivas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christ Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Foundation Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Heart Institute / Nebraska Heart Hospital</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health Cardiovascular Institute</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Health Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine St. Luke's Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia School of Medicine</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carilion Medical Center</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2016</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

